CL2012000948A1 - Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. - Google Patents
Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.Info
- Publication number
- CL2012000948A1 CL2012000948A1 CL2012000948A CL2012000948A CL2012000948A1 CL 2012000948 A1 CL2012000948 A1 CL 2012000948A1 CL 2012000948 A CL2012000948 A CL 2012000948A CL 2012000948 A CL2012000948 A CL 2012000948A CL 2012000948 A1 CL2012000948 A1 CL 2012000948A1
- Authority
- CL
- Chile
- Prior art keywords
- idm
- atanol
- propinate
- hfa
- fluticasone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0918150.4A GB0918150D0 (en) | 2009-10-16 | 2009-10-16 | Improved formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000948A1 true CL2012000948A1 (es) | 2012-12-14 |
Family
ID=41462451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000948A CL2012000948A1 (es) | 2009-10-16 | 2012-04-13 | Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. |
Country Status (24)
Country | Link |
---|---|
US (2) | US20120263766A1 (es) |
EP (2) | EP2488157B1 (es) |
JP (2) | JP5818801B2 (es) |
CN (1) | CN102573791B (es) |
AU (1) | AU2010305695B2 (es) |
BR (1) | BR112012008969B1 (es) |
CA (1) | CA2776845C (es) |
CL (1) | CL2012000948A1 (es) |
CY (1) | CY1123918T1 (es) |
DK (1) | DK2488157T3 (es) |
ES (1) | ES2859629T3 (es) |
GB (1) | GB0918150D0 (es) |
HR (1) | HRP20210379T1 (es) |
HU (1) | HUE054030T2 (es) |
IL (2) | IL219162A0 (es) |
LT (1) | LT2488157T (es) |
MX (1) | MX2012004338A (es) |
NZ (1) | NZ599900A (es) |
PL (1) | PL2488157T3 (es) |
PT (1) | PT2488157T (es) |
RS (1) | RS61430B1 (es) |
SI (1) | SI2488157T1 (es) |
WO (1) | WO2011045429A1 (es) |
ZA (1) | ZA201202595B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO121172B1 (ro) * | 2001-03-30 | 2007-01-30 | Jago Research Ag | Compoziţie farmaceutică de aerosol şi utilizarea acesteia |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
WO2013127738A1 (de) * | 2012-02-28 | 2013-09-06 | Boehringer Ingelheim International Gmbh | Neue treibgashaltige tiotropium-formulierung |
EP2836198A2 (en) | 2012-04-11 | 2015-02-18 | Cipla Limited | Pharmaceutical composition comprising arformoterol and fluticasone furoate |
GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
CN105963282B (zh) * | 2016-05-04 | 2019-04-19 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
WO2018059390A1 (zh) * | 2016-09-29 | 2018-04-05 | 广东东阳光药业有限公司 | 药物组合物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
JPH11509433A (ja) | 1995-04-14 | 1999-08-24 | グラクソ、ウェルカム、インコーポレーテッド | アルブテロール用計量投与用吸入器 |
RO119116B1 (ro) | 1995-04-14 | 2004-04-30 | Glaxo Wellcome Inc. | Inhalator pentru dozarea salmeterolului |
JPH101442A (ja) * | 1996-06-12 | 1998-01-06 | Taisho Pharmaceut Co Ltd | 鼻炎用点鼻薬 |
EP0969816B1 (en) * | 1997-03-20 | 2004-12-15 | Schering Corporation | Preparation of powder agglomerates |
GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
DZ3358A1 (fr) * | 2000-05-22 | 2001-11-29 | Chiesi Farma Spa | Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
WO2002024552A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Coated can for a metered dose inhaler |
WO2002030394A2 (en) * | 2000-10-09 | 2002-04-18 | 3M Innovative Properties Company | Medicinal aerosol formulations |
RO121172B1 (ro) * | 2001-03-30 | 2007-01-30 | Jago Research Ag | Compoziţie farmaceutică de aerosol şi utilizarea acesteia |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
GB0201400D0 (en) * | 2002-01-22 | 2002-03-13 | Glaxo Group Ltd | Novel apparatus and process |
JP2005539046A (ja) * | 2002-08-29 | 2005-12-22 | シプラ・リミテッド | 特異的な抗コリン作用薬、β−2アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物 |
GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0327727D0 (en) * | 2003-11-28 | 2003-12-31 | Quadrant Drug Delivery Ltd | Viral microparticles |
GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
-
2009
- 2009-10-16 GB GBGB0918150.4A patent/GB0918150D0/en not_active Ceased
-
2010
- 2010-10-15 CA CA2776845A patent/CA2776845C/en active Active
- 2010-10-15 MX MX2012004338A patent/MX2012004338A/es active IP Right Grant
- 2010-10-15 WO PCT/EP2010/065569 patent/WO2011045429A1/en active Application Filing
- 2010-10-15 AU AU2010305695A patent/AU2010305695B2/en active Active
- 2010-10-15 EP EP10768760.0A patent/EP2488157B1/en active Active
- 2010-10-15 PT PT107687600T patent/PT2488157T/pt unknown
- 2010-10-15 RS RS20210159A patent/RS61430B1/sr unknown
- 2010-10-15 EP EP20213235.3A patent/EP3811928A1/en not_active Withdrawn
- 2010-10-15 US US13/502,097 patent/US20120263766A1/en not_active Abandoned
- 2010-10-15 PL PL10768760T patent/PL2488157T3/pl unknown
- 2010-10-15 NZ NZ599900A patent/NZ599900A/en unknown
- 2010-10-15 BR BR112012008969-2A patent/BR112012008969B1/pt active IP Right Grant
- 2010-10-15 HU HUE10768760A patent/HUE054030T2/hu unknown
- 2010-10-15 JP JP2012533648A patent/JP5818801B2/ja active Active
- 2010-10-15 DK DK10768760.0T patent/DK2488157T3/da active
- 2010-10-15 SI SI201032050T patent/SI2488157T1/sl unknown
- 2010-10-15 CN CN201080046305.6A patent/CN102573791B/zh active Active
- 2010-10-15 LT LTEP10768760.0T patent/LT2488157T/lt unknown
- 2010-10-15 ES ES10768760T patent/ES2859629T3/es active Active
-
2012
- 2012-04-11 ZA ZA2012/02595A patent/ZA201202595B/en unknown
- 2012-04-13 CL CL2012000948A patent/CL2012000948A1/es unknown
- 2012-04-15 IL IL219162A patent/IL219162A0/en unknown
-
2015
- 2015-09-29 JP JP2015191177A patent/JP2016040286A/ja active Pending
-
2017
- 2017-03-21 US US15/464,879 patent/US20180296468A2/en not_active Abandoned
-
2019
- 2019-09-15 IL IL26936919A patent/IL269369A/en unknown
-
2021
- 2021-03-04 HR HRP20210379TT patent/HRP20210379T1/hr unknown
- 2021-03-05 CY CY20211100190T patent/CY1123918T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012000948A1 (es) | Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. | |
CL2009000602A1 (es) | Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclidinio equivalente a aproximadamente 400 microgramos de bromuro de aclidinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis. | |
MX2010003935A (es) | Suministro de farmaco por inhalacion. | |
AR079726A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes | |
CL2009000601A1 (es) | Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis. | |
ATE541603T1 (de) | Inhalator für pulverförmige substanzen | |
JP2010132695A5 (es) | ||
IL216467B (en) | Pharmaceutical compounds for administration by metered dose inhaler containing glycopyrrolate or formoterol and used for the treatment of respiratory diseases | |
CL2014002808A1 (es) | Dispositivo de inhalacion plegable para usar con un dispensador de inhalador de dosis medida, dicho dispositivo comprende un miembro de la extremidad de salida incluyendo una boquilla, un miembro de la extremidad de entrada incluyendo un orificio de entrada, y un miembro de manguito tubular; metodo para administrar una dosis de un medicamento; metodo para formar un dispositivo de inhalacion plegable. | |
AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
RS52940B (en) | PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS | |
UY34526A (es) | Un inhalador | |
JP2014530231A5 (es) | ||
CL2014003211A1 (es) | Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende | |
CO2022012449A2 (es) | Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada | |
WO2010011329A3 (en) | The delivery of powdered drug via inhalation | |
MX2014004364A (es) | Composiciones que comprenden sulfato de salbutamol. | |
DK2089008T3 (da) | Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator | |
NI201400139A (es) | Nueva forma de dosificación y formulación de abediterol | |
WO2011093820A3 (en) | A pharmaceutical combination comprising tiotropium | |
HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
IL201632A (en) | Use of Formoterol and Clomethazone Dipropionate-containing Preparations for the Preparation of Medication for Use in Acute Acute Episodes | |
CL2012000947A1 (es) | Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis. | |
BR112014008601A2 (pt) | fabricação de tubos de aerossol para insumos medicinais |